Contents

Search

fibroblast growth factor 23 (FGF23) in plasma

Clinical significance: - plasma levels elevated in tumor-induced osteomalacia - plasma levels elevated in hypophosphatemic rickets - higher plasma FGF-23 associated with increased risk for coronary artery disease [2] - plasma levels after stabilization from acute coronary syndrome associated with increased risk of major CV events (RR=1.4) & all-cause mortality (RR=2.3) [3] - more so in men than women - risk of CV death or heart failure (RR=3.1 vs 1.1 men vs women) - associated with myocardial fibrosis [3] - associated with upregulation of renin-angiotensin system [3] - high levels associated with secondary hyperparathyroidism & tertiary hyperparathyroidism [4] - elevated FGF-23 & PTH promote phosphorus excretion [4] Method: - plasma C-terminal FGF-23 concentration

Related

fibroblast growth factor 23; FGF-23; phosphatonin; tumor-derived hypophosphatemia-inducing factor; contains: fibroblast growth factor 23 N-terminal peptide; fibroblast growth factor 23 C-terminal peptide (FGF23, HYPF, UNQ3027/PRO9828)

General

fibroblast growth factor (FGF) in serum/plasma

References

  1. Loinc
  2. Panwar B, Judd SE, Wadley VG et al Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults. JAMA Cardiol. Published online March 7, 2018. PMID: 29516098 https://jamanetwork.com/journals/jamacardiology/fullarticle/2673604
  3. Bergmark BA, Udell JA, Morrow DA et al Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. Published online April 18, 2018 PMID: 29710336 https://jamanetwork.com/journals/jamacardiology/fullarticle/2678663
  4. Medical Knowledge Self Assessment Program (MKSAP) 19. American College of Physicians, Philadelphia 2021
  5. NEJM Knowledge+